Takeda Pharmaceutical Company Limited
TAK
$13.88
$0.010.07%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 7.52% | 37.67% | -55.27% | -56.59% | -36.63% |
| Total Depreciation and Amortization | -0.33% | 0.79% | 1.21% | 2.15% | 1.10% |
| Total Amortization of Deferred Charges | 13.61% | 13.61% | 13.61% | 13.61% | -21.40% |
| Total Other Non-Cash Items | 573.09% | 140.29% | 520.33% | 343.60% | -84.94% |
| Change in Net Operating Assets | 102.20% | -602.82% | -1,940.43% | -621.17% | -679.43% |
| Cash from Operations | 40.16% | -15.84% | -25.61% | -31.23% | -35.56% |
| Capital Expenditure | -9.35% | -19.53% | -18.47% | -16.34% | -9.74% |
| Sale of Property, Plant, and Equipment | -99.52% | -96.77% | 740.27% | 719.48% | 422.23% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 211.03% | 197.88% | 139.90% | 123.85% | -71.99% |
| Other Investing Activities | 69.17% | 74.08% | 72.72% | 37.05% | -706.41% |
| Cash from Investing | 56.63% | 59.47% | 59.40% | 28.17% | -317.99% |
| Total Debt Issued | 106.36% | 254.30% | 107.58% | 227.83% | -- |
| Total Debt Repaid | -154.68% | -18.12% | 27.60% | 6.14% | 9.77% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 19.09% | 19.09% | 19.09% | 91.36% | 95.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 3.33% | 3.14% | 3.95% | 2.69% | 2.45% |
| Other Financing Activities | -39.09% | -13.84% | 86.91% | 43.59% | 50.97% |
| Cash from Financing | -61.57% | 105.19% | 100.04% | 52.68% | 70.84% |
| Foreign Exchange rate Adjustments | -55.10% | -283.62% | 67.89% | 4.01% | -67.39% |
| Miscellaneous Cash Flow Adjustments | -1,575.00% | 10.67% | 101.39% | -1,283.33% | -166.67% |
| Net Change in Cash | 145.91% | 200.37% | 230.94% | 73.94% | -1,409.57% |